{"id":62305,"date":"2025-12-05T13:05:52","date_gmt":"2025-12-05T12:05:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/"},"modified":"2025-12-05T13:05:52","modified_gmt":"2025-12-05T12:05:52","slug":"natera-acquires-foresight-diagnostics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/","title":{"rendered":"Natera Acquires Foresight Diagnostics"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Expands Natera\u2019s lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm<sup>1<\/sup><\/i>\n<\/p>\n<p class=\"bwalignc\">\n<i>Cutting-edge IP adds to Natera\u2019s portfolio of &gt;500 issued or pending patents<\/i>\n<\/p>\n<p class=\"bwalignc\">\n<i>Accelerates Natera\u2019s expansion into lymphoma, where Foresight has developed a strong clinical position<\/i>\n<\/p>\n<p>AUSTIN, Texas &amp; BOULDER, Colo.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54370090&amp;newsitemid=20251205184980&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=48c1d6126758eb5642aeab7562a62634\" rel=\"nofollow\" shape=\"rect\">Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251205184980\/en\/1736351\/4\/Natera_floret_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251205184980\/en\/1736351\/22\/Natera_floret_Logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251205184980\/en\/1736351\/4\/Natera_floret_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251205184980\/en\/1736351\/21\/Natera_floret_Logo.jpg\"><\/a><\/p>\n<p>\nForesight is a cancer diagnostics company and CLIA-registered laboratory. The company\u2019s circulating tumor DNA (ctDNA)-based MRD tests leverage its patented PhasED-Seq\u2122 technology, targeting phased variants. With this technology, Foresight has reported performance with LOD95 of 0.3 parts per million and detection below 0.1 ppm<sup>1<\/sup>.\n<\/p>\n<p>\nForesight was founded by Stanford University physicians and scientists, Maximilian Diehn, M.D., Ph.D., Ash Alizadeh, M.D., Ph.D., and David Kurtz, M.D., Ph.D., together with Jake Chabon, Ph.D., Foresight\u2019s chief scientific officer and chief executive officer. The company has authored more than 40 scientific publications and presentations and partnered with more than 30 biopharma and academic researchers.\n<\/p>\n<p>\n<span class=\"bwuline\">Strategic Rationale<\/span>\n<\/p>\n<p>\nThe transaction combines Natera\u2019s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight\u2019s unique phased variant technology and leadership in lymphoma. It builds on Natera\u2019s broad intellectual property portfolio for tumor-informed and personalized MRD products<b> <\/b>including in phased variants,<b> <\/b>and promises to accelerate MRD adoption in lymphoma and other solid tumor types.\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Signatera<\/b><b>\u2122<\/b><b> platform with phased variants:<\/b> The integration of phased variants into the Signatera platform will further differentiate and strengthen test performance across solid tumors. This enhanced version is available immediately for research use for biopharma and academic partners and is expected to be launched for clinical use in 2026.\n<\/li>\n<li>\n<b>Leadership in lymphoma:<\/b> The transaction builds on Foresight\u2019s clinical research momentum in B-cell lymphomas, a large patient population with more than 75,000 new cases annually in the U.S.<sup>2<\/sup> Earlier this year, Foresight data provided the foundation for the inclusion of ctDNA MRD into the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) Clinical Practice Guidelines for diffuse large B-cell lymphoma. Additionally, Foresight\u2019s CLARITY\u2122 MRD assay for lymphoma is being used in three prospective MRD-driven clinical trials informing treatment decisions for patients. Foresight CLARITY joins Natera\u2019s extensive MRD product portfolio and will continue to support clinical trials, translational research and future applications.\n<\/li>\n<\/ul>\n<p>\nAt the American Society of Hematology (ASH) Annual Meeting beginning on December 6, Natera and Foresight will have a total of 15 abstracts featuring Signatera and PhasED-Seq, including seven oral presentations.\n<\/p>\n<p>\n<span class=\"bwuline\">Transaction Terms<\/span>\n<\/p>\n<p>\nNatera has closed the acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones.\n<\/p>\n<p>\n\u201cThis acquisition reinforces Natera\u2019s position at the forefront of precision oncology,\u201d said Steve Chapman, chief executive officer of Natera. \u201cForesight\u2019s phased variant technology and leadership in lymphoma complement Natera\u2019s strong capabilities in personalized MRD testing, improving the value we can deliver to patients, clinicians, biopharma partners and the broader healthcare system.\u201d\n<\/p>\n<p>\n\u201cForesight\u2019s mission has always been to improve the lives of cancer patients worldwide through innovative diagnostics,\u201d said Chabon. \u201cAs we join Natera, I\u2019m deeply grateful to our employees, partners and investors who have helped bring us to this moment. Together, we can realize this mission on a far greater scale, accelerating the pace of discovery across both hematologic and solid tumors.\u201d\n<\/p>\n<p>\nGibson, Dunn &amp; Crutcher LLP is serving as legal counsel to Natera. Wilson Sonsini Goodrich &amp; Rosati is serving as legal counsel to Foresight, while Centerview Partners LLC is acting as its financial advisor.\n<\/p>\n<p>\n<b>References<\/b>\n<\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nCabel L, Jeon YJ, Parikh AR, et al. Ultrasensitive Phased Variant Detection Enables Improved ctDNA-Based MRD Assessment Across Solid Tumors. Presented at: European Society for Medical Oncology (ESMO) Annual Meeting; 2024.\n<\/li>\n<li>\nAmerican Cancer Society. <i>Types of B-cell Lymphoma.<\/i> American Cancer Society. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cancer.org%2Fcancer%2Ftypes%2Fnon-hodgkin-lymphoma%2Fabout%2Fb-cell-lymphoma.html&amp;esheet=54370090&amp;newsitemid=20251205184980&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.cancer.org%2Fcancer%2Ftypes%2Fnon-hodgkin-lymphoma%2Fabout%2Fb-cell-lymphoma.html&amp;index=2&amp;md5=5f4700f399a37c6c58430f57803b43c2\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.cancer.org\/cancer\/types\/non-hodgkin-lymphoma\/about\/b-cell-lymphoma.html<\/a>. Accessed November 26, 2025.\n<\/li>\n<\/ol>\n<p>\n<b>About Natera<\/b>\n<\/p>\n<p>\nNatera\u2122 is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 325 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54370090&amp;newsitemid=20251205184980&amp;lan=en-US&amp;anchor=www.natera.com&amp;index=3&amp;md5=32ba796ff21e7499ac03c0d4c5e22ed9\" rel=\"nofollow\" shape=\"rect\">www.natera.com<\/a>.\n<\/p>\n<p>\n<b>Forward-Looking Statements<\/b>\n<\/p>\n<p>\nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements, including those regarding the expected benefits of the Foresight acquisition, integration of technologies, clinical and commercial opportunities, and future performance, represent Natera\u2019s expectations as of the date of this press release, and are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the ability to integrate Foresight\u2019s business, realize anticipated benefits, achieve expected clinical or commercial outcomes, obtain or maintain reimbursement coverage, and respond to competitive or regulatory developments. Additional risks and uncertainties are discussed in greater detail in \u201cRisk Factors\u201d in Natera\u2019s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2Finvestors&amp;esheet=54370090&amp;newsitemid=20251205184980&amp;lan=en-US&amp;anchor=www.natera.com%2Finvestors&amp;index=4&amp;md5=8638e5b7a2061d6d48d1eeb057cf3752\" rel=\"nofollow\" shape=\"rect\">www.natera.com\/investors<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54370090&amp;newsitemid=20251205184980&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=b657881c2e7ceac04e7befc8fa69c941\" rel=\"nofollow\" shape=\"rect\">www.sec.gov<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., <a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;&#x3a;i&#110;&#x76;e&#115;&#x74;&#x6f;r&#64;&#x6e;a&#116;&#x65;&#x72;a&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow\" shape=\"rect\">&#x69;&#x6e;&#x76;&#x65;&#115;&#116;or&#64;&#x6e;&#x61;&#x74;&#x65;&#114;&#97;&#46;co&#x6d;<\/a><br \/>Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., <a target=\"_blank\" href=\"&#x6d;&#x61;&#105;l&#x74;&#x6f;&#58;pr&#x40;&#x6e;&#97;t&#x65;&#x72;&#97;&#46;c&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x70;&#x72;&#x40;&#x6e;&#x61;&#x74;&#x65;&#x72;&#97;&#46;&#99;&#111;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Expands Natera\u2019s lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera\u2019s portfolio of &gt;500 issued or pending patents Accelerates Natera\u2019s expansion into lymphoma, where Foresight has developed a strong clinical position AUSTIN, Texas &amp; BOULDER, Colo.&#8211;(BUSINESS &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62305","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Natera Acquires Foresight Diagnostics - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Natera Acquires Foresight Diagnostics - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Expands Natera\u2019s lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera\u2019s portfolio of &gt;500 issued or pending patents Accelerates Natera\u2019s expansion into lymphoma, where Foresight has developed a strong clinical position AUSTIN, Texas &amp; BOULDER, Colo.&#8211;(BUSINESS ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-05T12:05:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251205184980\/en\/1736351\/22\/Natera_floret_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Natera Acquires Foresight Diagnostics\",\"datePublished\":\"2025-12-05T12:05:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/\"},\"wordCount\":965,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251205184980\\\/en\\\/1736351\\\/22\\\/Natera_floret_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/\",\"name\":\"Natera Acquires Foresight Diagnostics - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251205184980\\\/en\\\/1736351\\\/22\\\/Natera_floret_Logo.jpg\",\"datePublished\":\"2025-12-05T12:05:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251205184980\\\/en\\\/1736351\\\/22\\\/Natera_floret_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251205184980\\\/en\\\/1736351\\\/22\\\/Natera_floret_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/natera-acquires-foresight-diagnostics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Natera Acquires Foresight Diagnostics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Natera Acquires Foresight Diagnostics - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/","og_locale":"en_US","og_type":"article","og_title":"Natera Acquires Foresight Diagnostics - Pharma Trend","og_description":"Expands Natera\u2019s lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera\u2019s portfolio of &gt;500 issued or pending patents Accelerates Natera\u2019s expansion into lymphoma, where Foresight has developed a strong clinical position AUSTIN, Texas &amp; BOULDER, Colo.&#8211;(BUSINESS ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/","og_site_name":"Pharma Trend","article_published_time":"2025-12-05T12:05:52+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251205184980\/en\/1736351\/22\/Natera_floret_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Natera Acquires Foresight Diagnostics","datePublished":"2025-12-05T12:05:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/"},"wordCount":965,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251205184980\/en\/1736351\/22\/Natera_floret_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/","url":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/","name":"Natera Acquires Foresight Diagnostics - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251205184980\/en\/1736351\/22\/Natera_floret_Logo.jpg","datePublished":"2025-12-05T12:05:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251205184980\/en\/1736351\/22\/Natera_floret_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251205184980\/en\/1736351\/22\/Natera_floret_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/natera-acquires-foresight-diagnostics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Natera Acquires Foresight Diagnostics"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62305"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62305\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}